# U.S. Food and Drug Administration (FDA)

Type: regulator

Source: GetYourBrief — https://getyourbrief.com/entity/us-food-and-drug-administration-fda-regulator
Canonical HTML page: https://getyourbrief.com/entity/us-food-and-drug-administration-fda-regulator

## Timeline

- **2026-07-17**: FDA links outbreak to Taco Bell lettuce — FDA announces traceback results identifying shredded iceberg lettuce from Mexico as the source; Taylor Farms announces voluntary removal of all central Mexican iceberg lettuce from U.S. market.
- **2026-07-13**: Last illness onset — Final reported onset date within the outbreak window.
- **2026-Q3**: Comment Period Close — Expected deadline for industry stakeholders to submit feedback on the proposed framework.
- **2026-05-13**: First illness onset — First reported case of cyclospora infection linked to the outbreak.
- **2026-02-24**: Customized Drug Proposal — FDA formally proposes the new system for approving bespoke therapies for rare diseases.
- **2026-02-23**: Quicker Path Formalized — Official rollout of the streamlined regulatory framework for gene therapy approvals.
- **2025-06-15**: CBER Staffing Surge — FDA completes hiring of 100+ new reviewers dedicated to biologics and gene therapy.
- **2024-06**: SCOTUS Ruling — Supreme Court preserves access to mifepristone by ruling plaintiffs lacked standing in FDA challenge.
- **2024-03-26**: SCOTUS Mifepristone Hearing — Supreme Court hears arguments regarding the FDA's regulation of medication abortion pills.
- **2024-03-23**: National Data Release — Reports confirm U.S. abortion numbers held steady despite 14 state-level bans.
- **2023-05-01**: START Pilot Program — FDA launches the Support for clinical Trials Advancing Rare disease Therapeutics pilot.
- **2023-01-01**: Shield Law Expansion — States like MA and NY implement laws protecting providers from out-of-state legal actions.
- **2022-12**: FDORA Enacted — The Food and Drug Omnibus Reform Act authorizes the FDA to establish a Platform Technology Designation.
- **2022-06-24**: Dobbs Decision — U.S. Supreme Court overturns Roe v. Wade, returning abortion regulation to the states.
- **2022-06**: Dobbs Decision — SCOTUS overturns Roe v. Wade, triggering state-level bans and increasing demand for pills.

## Recent coverage (12 stories, network-wide)

### Taylor Farms Pulls Mexican Lettuce After 1,644 Cyclospora Illnesses
2026-07-18 00:25:30 · Sector: supply · Sentiment: Negative · Impact: 7/10 · Sources: 3

Taco Bell’s lettuce supplier halts all Mexican imports after FDA traceback links 1,644 cyclospora cases to a single farm. The recall spotlights fresh-produce supply chain vulnerabilities and traceability gaps.
Full story: https://getsupplybrief.com/story/taylor-farms-supply-chain-cyclospora-outbreak

### 42% Proteinuria Cut: FDA Backs Vera’s IgAN Drug with Accelerated Approval
2026-07-12 07:12:03 · Sector: health · Sentiment: Positive · Impact: 8/10 · Sources: 2

The FDA’s accelerated approval of TRUTAKNA marks the first BAFF/APRIL inhibitor for IgA nephropathy, showing a 42% UPCR reduction over placebo. Healthcare providers now have a therapy targeting upstream disease drivers, with launch imminent and a confirmatory trial ongoing.
Full story: https://gethealthbrief.com/story/trutakna-accelerated-approval-iga-nephropathy-health

### Vera’s TRUTAKNA Gets FDA Nod with 42% UPCR Reduction, Awaits Kidney Data
2026-07-12 07:11:54 · Sector: bio · Sentiment: Positive · Impact: 8/10 · Sources: 2

Vera Therapeutics scores an accelerated approval for TRUTAKNA in IgA nephropathy, touting a 42% UPCR reduction vs placebo in Phase 3 ORIGIN 3. The dual BAFF/APRIL inhibitor enters a competitive market with a surrogate endpoint—investors await the confirmatory eGFR data.
Full story: https://getbiobrief.com/story/vera-trutakna-fda-accelerated-approval-iga-nephropathy

### Solius Labs Launches Solius Pro with 99% Less UV Risk, Targets Home Market
2026-06-18 01:32:51 · Sector: startups · Sentiment: Positive · Impact: 7/10 · Sources: 2

Bainbridge Island-based startup Solius Labs announces the launch of its FDA-cleared personalized sunlight device, Solius Pro, targeting the growing consumer health and wellness market. The move positions the company at the forefront of a new category of over-the-counter light therapy without prescription.
Full story: https://getstartupbrief.com/story/solius-labs-launch-solius-pro-99-less-uv-risk-home-market

### Solius Pro Delivers UVB Therapy in 5 Minutes Weekly with 99% Less UV Risk
2026-06-18 01:32:45 · Sector: health · Sentiment: Positive · Impact: 7/10 · Sources: 2

Solius Labs launches the first OTC FDA-cleared personalized UVB light therapy device, claiming significant health benefits with minimal UV risk. For health consumers, it could offer a convenient way to boost vitamin D and improve mood without sun exposure.
Full story: https://gethealthbrief.com/story/solius-pro-uvb-therapy-5-minutes-99-less-risk

### FDA Creates New Product Code for Solius Pro UVB Device, Cutting UV Risk 99%
2026-06-18 01:32:38 · Sector: bio · Sentiment: Positive · Impact: 7/10 · Sources: 2

The FDA has established a novel product code for Solius Pro, an over-the-counter UVB light therapy device that claims to deliver biological benefits of sunlight with dramatically reduced risk. The move signals regulatory recognition of personalized home phototherapy as a distinct category.
Full story: https://getbiobrief.com/story/fda-new-product-code-solius-pro-uvb-99-risk-reduction

### Medication Abortion Dominates US Market Amid Escalating Regulatory Warfare
2026-03-24 07:47:20 · Sector: bio · Sentiment: Neutral · Impact: 7/10 · Sources: 2

Medication abortion has surged to account for the majority of pregnancy terminations in the U.S., driven by telehealth expansion and mail-order access. This shift has catalyzed a sophisticated legal and legislative counter-offensive aimed at the FDA's regulatory authority and the distribution of pharmaceutical products.
Full story: https://getbiobrief.com/story/medication-abortion-market-trends-2026

### U.S. Abortion Rates Stabilize Amid Regulatory Fragmentation and Shield Laws
2026-03-24 07:41:40 · Sector: legal · Sentiment: Neutral · Impact: 7/10 · Sources: 10

Despite the implementation of near-total bans in 14 states, the national volume of abortions in the U.S. has remained steady or increased. This resilience is driven by a surge in medication abortion, the expansion of telehealth, and the emergence of state 'shield laws' that protect providers across jurisdictional lines.
Full story: https://getlegalbrief.com/story/us-abortion-rates-stability-regulation-shield-laws

### FDA Launches Performance Bonuses to Accelerate Drug Review Timelines
2026-02-26 23:39:45 · Sector: health · Sentiment: Positive · Impact: 7/10 · Sources: 5

The U.S. Food and Drug Administration is introducing a new incentive program that provides financial bonuses to staff members who complete drug application reviews ahead of schedule. This move aims to streamline the regulatory pipeline and reduce the backlog of pending therapies, though it raises questions regarding the balance between speed and clinical rigor.
Full story: https://gethealthbrief.com/story/fda-bonus-payments-speedy-drug-reviews

### FDA Unveils Regulatory Framework for Bespoke Rare Disease Therapies
2026-02-24 03:15:59 · Sector: legal · Sentiment: Positive · Impact: 8/10 · Sources: 2

The FDA has proposed a landmark regulatory system designed to accelerate the approval of customized, 'bespoke' medicines for ultra-rare diseases. The framework allows manufacturers to leverage data from established platform technologies to streamline the development of individualized genomic treatments.
Full story: https://getlegalbrief.com/story/fda-bespoke-drug-approval-framework

### FDA Accelerates Gene Therapy Approvals with New Regulatory Framework
2026-02-23 22:39:08 · Sector: health · Sentiment: Positive · Impact: 8/10 · Sources: 8

The FDA has launched a streamlined regulatory pathway designed to expedite the development and review of gene therapies, particularly for rare diseases. This initiative marks a significant shift toward using surrogate endpoints and flexible trial designs to bring life-saving treatments to market faster.
Full story: https://gethealthbrief.com/story/fda-quicker-path-gene-therapies-regulation

### NG Biotech and Hardy Diagnostics Secure FDA Breakthrough for AMR Assays
2026-02-19 11:10:27 · Sector: health · Sentiment: Positive · Impact: 7/10 · Sources: 2

NG Biotech and Hardy Diagnostics have received FDA Breakthrough Device Designation for two rapid diagnostic assays targeting multidrug-resistant pathogens. The NG-TEST Candida auris and NG-TEST Aci assays provide rapid, point-of-care identification of high-priority healthcare-associated infections.
Full story: https://gethealthbrief.com/story/ng-biotech-hardy-diagnostics-fda-breakthrough-amr

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.